(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

SBRT is an effective treatment modality, achieving excellent local control with minimal toxicity for patients with adrenal metastases. The development of progressive distant metastasis is the predominant pattern of failure affecting patients’ survival outcomes.

William W. Chance, MD, Quynh-Nhu Nguyen, MD, Reza J. Mehran, MD, James W. Welsh, MD, Daniel R. Gomez, MD, Peter A. Balter, PhD, Ritsuko Komaki, MD, Zhongxing Liao, MD, Joe Y. Chang, MD, PhD; UT MD Anderson Cancer Center

PURPOSE: A single-institution, retrospective review of toxicity, patterns of failure, and outcomes in patients undergoing stereotactic body radiotherapy (SBRT) for metastasis to the adrenal gland.

MATERIALS AND METHODS: From 2009–2014, a total of 36 patients with 40 adrenal metastases were treated with SBRT. The median age of the patient population was 63.7 years (range: 50–77 yr). Primary sites included lung (n = 31), ovary (n = 2), bladder (n = 1), esophagus (n = 1), and melanoma (n = 1). A total of 32 patients received treatment to a single adrenal gland, while 4 patients received treatment to the bilateral adrenal glands. The prescription dose to the target was 60 Gy in 10 fractions (n = 25), 50 Gy in 10 fractions (n = 10), 50 Gy in 4 fractions (n = 4), or other (n = 4). Failures within the prescribed high-dose irradiated region were considered local failures. New or progressive distant metastases outside of the treated adrenal gland were considered distant failures. After review of the radiation treatment plan, local failures were characterized as in-field (epicenter within the 100% isodose line) or marginal (between the 50% and 100% isodose lines).

RESULTS: Median follow-up was 12.6 months after radiation treatment (range: 1.4–37.1 mo). Six patients developed grade 1 gastrointestinal toxicity. Two patients who were treated to the bilateral adrenal glands developed grade 2 adrenal insufficiency. There was no grade 3 or 4 toxicity observed. Median overall survival after treatment was 19.5 months. The 1- and 2-year overall survival rates were 67% and 55%, respectively. The 1-year freedom from local failure was 87%. The median time to local failure was not reached. The 1-year freedom from disease progression was 25% (median time to progression, 5.9 mo). The 1-year freedom from distant failure was 33% (median time to distant failure, 6.0 mo). There were six in-field local failures and one marginal failure observed.

CONCLUSION: SBRT is an effective treatment modality, achieving excellent local control with minimal toxicity for patients with adrenal metastases. The development of progressive distant metastasis is the predominant pattern of failure affecting patients’ survival outcomes.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Related Content